1. Home
  2. NGVT vs AUPH Comparison

NGVT vs AUPH Comparison

Compare NGVT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ingevity Corporation

NGVT

Ingevity Corporation

HOLD

Current Price

$76.61

Market Cap

2.1B

Sector

Industrials

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$16.09

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGVT
AUPH
Founded
1964
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
NGVT
AUPH
Price
$76.61
$16.09
Analyst Decision
Buy
Buy
Analyst Count
2
4
Target Price
$72.50
$17.25
AVG Volume (30 Days)
262.1K
1.1M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
61.10
5075.00
EPS
N/A
2.07
Revenue
$1,167,600,000.00
$283,055,000.00
Revenue This Year
$3.63
$17.54
Revenue Next Year
$0.50
$15.74
P/E Ratio
N/A
$7.75
Revenue Growth
N/A
20.38
52 Week Low
$30.19
$7.29
52 Week High
$77.46
$16.54

Technical Indicators

Market Signals
Indicator
NGVT
AUPH
Relative Strength Index (RSI) 68.42 65.87
Support Level $63.60 $14.56
Resistance Level $77.23 $16.28
Average True Range (ATR) 1.97 0.53
MACD 0.75 0.14
Stochastic Oscillator 94.58 87.56

Price Performance

Historical Comparison
NGVT
AUPH

About NGVT Ingevity Corporation

Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: